Inhibrx Stock Based Compensation vs Net Income Analysis

INBX Stock  USD 20.98  0.04  0.19%   
Inhibrx Biosciences, financial indicator trend analysis is infinitely more than just investigating Inhibrx Biosciences, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inhibrx Biosciences, is a good investment. Please check the relationship between Inhibrx Biosciences, Stock Based Compensation and its Net Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx Biosciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx Biosciences, guide.

Stock Based Compensation vs Net Income

Stock Based Compensation vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inhibrx Biosciences, Stock Based Compensation account and Net Income. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Inhibrx Biosciences,'s Stock Based Compensation and Net Income is 0.89. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Net Income in the same time period over historical financial statements of Inhibrx Biosciences,, assuming nothing else is changed. The correlation between historical values of Inhibrx Biosciences,'s Stock Based Compensation and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Inhibrx Biosciences, are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Stock Based Compensation i.e., Inhibrx Biosciences,'s Stock Based Compensation and Net Income go up and down completely randomly.

Correlation Coefficient

0.89
Relationship DirectionPositive 
Relationship StrengthStrong

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Inhibrx Biosciences, financial statement analysis. It represents the amount of money remaining after all of Inhibrx Biosciences, operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most indicators from Inhibrx Biosciences,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inhibrx Biosciences, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx Biosciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx Biosciences, guide.At this time, Inhibrx Biosciences,'s Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to 2,133 in 2025, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2025.
 2022 2023 2024 2025 (projected)
Total Operating Expenses131.3M219.8M331.6M348.2M
Cost Of Revenue2.8M1.2M2.3M2.2M

Inhibrx Biosciences, fundamental ratios Correlations

0.830.910.870.670.7-0.74-0.920.651.00.751.00.110.750.270.831.0-0.51-0.58-0.36-0.170.980.460.34-0.060.66
0.830.680.620.190.35-0.24-0.930.290.840.380.840.580.960.070.950.84-0.07-0.33-0.20.020.840.040.66-0.50.42
0.910.680.960.640.73-0.73-0.860.670.890.80.89-0.020.630.220.740.9-0.45-0.54-0.27-0.110.910.550.180.020.87
0.870.620.960.60.85-0.73-0.830.810.850.880.85-0.120.620.350.740.86-0.48-0.41-0.29-0.240.870.470.150.030.81
0.670.190.640.60.57-0.97-0.40.610.670.640.67-0.420.030.330.170.66-0.8-0.71-0.3-0.270.650.78-0.190.470.57
0.70.350.730.850.57-0.72-0.560.850.660.970.66-0.340.410.440.530.67-0.69-0.09-0.43-0.370.640.38-0.10.310.51
-0.74-0.24-0.73-0.73-0.97-0.720.47-0.74-0.72-0.79-0.720.48-0.14-0.37-0.29-0.720.790.650.390.3-0.69-0.780.21-0.48-0.63
-0.92-0.93-0.86-0.83-0.4-0.560.47-0.54-0.92-0.58-0.92-0.39-0.88-0.18-0.93-0.930.260.430.110.07-0.96-0.22-0.560.4-0.67
0.650.290.670.810.610.85-0.74-0.540.630.830.63-0.40.310.660.440.63-0.68-0.3-0.15-0.590.620.290.120.170.45
1.00.840.890.850.670.66-0.72-0.920.630.711.00.140.760.270.831.0-0.5-0.6-0.35-0.170.980.450.36-0.080.64
0.750.380.80.880.640.97-0.79-0.580.830.710.71-0.390.420.330.550.72-0.67-0.25-0.47-0.240.680.52-0.150.40.59
1.00.840.890.850.670.66-0.72-0.920.631.00.710.140.760.270.831.0-0.5-0.6-0.35-0.170.980.450.36-0.080.64
0.110.58-0.02-0.12-0.42-0.340.48-0.39-0.40.14-0.390.140.53-0.270.430.140.370.150.340.30.21-0.460.68-0.84-0.04
0.750.960.630.620.030.41-0.14-0.880.310.760.420.760.530.030.980.760.05-0.16-0.250.050.74-0.040.59-0.510.36
0.270.070.220.350.330.44-0.37-0.180.660.270.330.27-0.270.030.10.26-0.540.04-0.03-0.990.26-0.220.3-0.060.0
0.830.950.740.740.170.53-0.29-0.930.440.830.550.830.430.980.10.84-0.07-0.23-0.290.00.820.080.53-0.420.49
1.00.840.90.860.660.67-0.72-0.930.631.00.721.00.140.760.260.84-0.49-0.59-0.34-0.160.980.450.36-0.090.65
-0.51-0.07-0.45-0.48-0.8-0.690.790.26-0.68-0.5-0.67-0.50.370.05-0.54-0.07-0.490.280.150.51-0.49-0.380.08-0.46-0.25
-0.58-0.33-0.54-0.41-0.71-0.090.650.43-0.3-0.6-0.25-0.60.15-0.160.04-0.23-0.590.280.05-0.09-0.57-0.7-0.1-0.17-0.53
-0.36-0.2-0.27-0.29-0.3-0.430.390.11-0.15-0.35-0.47-0.350.34-0.25-0.03-0.29-0.340.150.050.03-0.19-0.420.44-0.48-0.08
-0.170.02-0.11-0.24-0.27-0.370.30.07-0.59-0.17-0.24-0.170.30.05-0.990.0-0.160.51-0.090.03-0.150.27-0.260.030.1
0.980.840.910.870.650.64-0.69-0.960.620.980.680.980.210.740.260.820.98-0.49-0.57-0.19-0.150.420.41-0.190.72
0.460.040.550.470.780.38-0.78-0.220.290.450.520.45-0.46-0.04-0.220.080.45-0.38-0.7-0.420.270.42-0.560.60.67
0.340.660.180.15-0.19-0.10.21-0.560.120.36-0.150.360.680.590.30.530.360.08-0.10.44-0.260.41-0.56-0.8-0.05
-0.06-0.50.020.030.470.31-0.480.40.17-0.080.4-0.08-0.84-0.51-0.06-0.42-0.09-0.46-0.17-0.480.03-0.190.6-0.80.01
0.660.420.870.810.570.51-0.63-0.670.450.640.590.64-0.040.360.00.490.65-0.25-0.53-0.080.10.720.67-0.050.01
Click cells to compare fundamentals

Inhibrx Biosciences, Account Relationship Matchups

Inhibrx Biosciences, fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets143.7M150.5M290.9M307.9M180.8M140.4M
Short Long Term Debt Total37.5M70.5M202.1M210.1M8.0M7.6M
Other Current Liab13.4M9.6M19.3M43.9M29.9M15.2M
Total Current Liabilities31.4M22.5M27.6M56.3M40.7M28.0M
Total Stockholder Equity75.5M52.4M58.1M43.5M133.6M140.3M
Property Plant And Equipment Net11.3M9.5M7.2M9.4M13.5M8.2M
Net Debt(91.2M)(60.8M)(71.8M)(67.8M)(144.5M)(137.3M)
Retained Earnings(145.4M)(227.1M)(372.4M)(613.7M)(106.1M)(111.4M)
Accounts Payable13.5M9.1M4.3M8.3M9.2M6.7M
Cash128.7M131.3M273.9M277.9M152.6M123.6M
Non Current Assets Total11.6M11.3M10.4M12.5M20.4M10.3M
Cash And Short Term Investments128.7M131.3M273.9M277.9M152.6M123.6M
Common Stock Shares Outstanding25.3M38.0M40.1M47.1M14.5M26.1M
Liabilities And Stockholders Equity143.7M150.5M290.9M307.9M180.8M140.4M
Non Current Liabilities Total36.9M75.6M205.2M208.1M6.5M6.1M
Other Current Assets132.2M7.8M5.5M16.7M6.9M6.6M
Total Liab68.3M98.1M232.8M264.4M47.2M44.8M
Total Current Assets132.2M139.1M280.5M295.4M160.4M130.1M
Short Term Debt1.5M1.7M3.7M4.1M1.6M2.9M
Current Deferred Revenue7.9M3.1M2.0M166K149.4K141.9K
Net Receivables615K878K257K778K420K477.2K
Inventory3.2M(129.3M)(878K)(257K)(231.3K)(242.9K)
Other Stockholder Equity220.8M279.5M430.4M657.2M239.7M236.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx Biosciences,'s price analysis, check to measure Inhibrx Biosciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx Biosciences, is operating at the current time. Most of Inhibrx Biosciences,'s value examination focuses on studying past and present price action to predict the probability of Inhibrx Biosciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx Biosciences,'s price. Additionally, you may evaluate how the addition of Inhibrx Biosciences, to your portfolios can decrease your overall portfolio volatility.